Introduction
============

Gastric cancer is the third leading cause of cancer-associated mortality worldwide ([@b1-ol-0-0-11626]). Locally advanced gastric cancer (LAGC) is a major treatment challenge and accounts for 80% of total gastric cancer cases in China ([@b2-ol-0-0-11626],[@b3-ol-0-0-11626]). The current therapeutic strategy for LAGC is multidisciplinary with a surgical procedure as the core. Accumulating evidence has revealed that neoadjuvant therapy improves the efficacy of LAGC compared with surgery alone ([@b4-ol-0-0-11626]--[@b7-ol-0-0-11626]).

Since the 2014 version of the guidelines of the Japan Society for Endoscopic Surgery, distal gastrectomy by the laparoscopic approach was recommended for stage I gastric cancer ([@b8-ol-0-0-11626]). For advanced gastric cancer following neoadjuvant therapy, however, the safety and efficacy of laparoscopic approach following were unclear, as oncologic outcomes of currently ongoing randomized trials are unknown ([@b9-ol-0-0-11626],[@b10-ol-0-0-11626]). A number of surgeons are now actively applying laparoscopic gastrectomy (LG) to patients with LAGC receiving neoadjuvant therapy. To the best of our knowledge, a limited number of studies have reported the safety and efficacy of LG following neoadjuvant therapy, particularly in terms of long-time survival.

Therefore, the aim of the present study was to evaluate the postoperative safety and efficacy and the long-time survival of patients who had undergone LG compared with patients who had undergone open gastrectomy (OG) following neoadjuvant therapy.

Patients and methods
====================

### Patient selection

This study retrospectively reviewed the medical records of 270 patients with LAGC who underwent LG (n=49) or conventional OG (n=221) surgery following neoadjuvant therapy between January 2007 and December 2016 at the China National Cancer Center (Beijing, China). LAGC was defined as clinical stage II--III according to the eighth edition American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) Tumor-Node-Metastasis (TNM) gastric cancer classification ([@b11-ol-0-0-11626]). There were 188 male (69.6%) and 82 female (30.4%) patients (male-to-female ratio, 2.29:1; median age, 54.8 years; range, 28--84 years). The database included data on patient demographics, clinical history, past medical history, family history, comorbidities, diagnostic tests, tumor characteristics, therapeutic interventions, pathological data, postoperative parameters and survival outcomes. All data were backed up by source documents and the accuracy of the data was periodically reviewed. The study procedures were approved by the Institutional Review Board at the China National Cancer Center and the patients provided informed consent at the time of sample collection.

### Procedures

Patients received a fluoropyrimidine-based chemoradiotherapy regimen preoperatively. Surgery was performed 2--8 weeks after completion of the neoadjuvant therapy. Histopathological examination was evaluated according to the Mandard Tumor Regression Grading evaluation system ([@b12-ol-0-0-11626]).

### Follow-up

Patients were followed-up every 3 months for the first 2 years, every 6 months for the next 3 years, and every 6 months or yearly thereafter. For the postoperative follow-up, a physical examination, complete blood-cell count, liver function tests, serum carcinoembryonic antigen tests and chest radiography were performed every 3 months or 6 months; abdominal and pelvic computed tomography (CT) were performed every 6 months. Gastroscopic examinations were done 1 year postoperatively and once every 2 years thereafter. When a patient missed two consecutive scheduled visits or voluntarily withdrew consent to participate during the follow-up period, the patient was defined as lost to follow-up and their data were censored. The last follow-up was completed in May 2017 and included 251 patients.

### Statistical analysis

Data of continuous variables are presented as the mean ± standard deviation, whereas categorical variable data were presented as percentages. Patient demographic and clinical characteristics between the two groups were compared with Student\'s t-test for continuous variables with normal distribution and χ^2^ test for categorical variables. The Kaplan-Meier method was used to estimate disease-free survival (DFS) and overall survival (OS) rates, and the log-rank test was used to compare survival distribution. Multivariate Cox regression analysis was used to adjust for confounding factors that were significant in univariate analysis and for non-balanced between-group variables. Mean survival time (months) and 95% confidence interval (CI) were calculated using the Kaplan-Meier method. A two-sided P\<0.05 was considered to indicate a statistically significant difference. All analyses were performed using SPSS statistical software version 24.0 (SPSS, Inc.).

Results
=======

Between January 2007 and December 2016, 270 patients that underwent neoadjuvant therapy received LG (n=49) or OG (n=221). None of the patients had a metastatic lesion detected before or during the surgery. There were no deaths during the first 3 months after surgery. The OG and LG groups were balanced in terms of their baseline characteristics, combined comorbidities, clinical staging before neoadjuvant therapy, and chemotherapy regimens. The number of neoadjuvant therapy cycles was statistically different between the two groups (P=0.016). According to RECIST criteria (version 1.1) ([@b13-ol-0-0-11626]) and tumor regression grade, response on neoadjuvant therapy was not significantly different between the two groups ([Table I](#tI-ol-0-0-11626){ref-type="table"}).

Postoperative stay was shorter and the number of metastatic lymph nodes harvested was lower in the LG group compared with that in the OG group ([Tables I](#tI-ol-0-0-11626){ref-type="table"} and [II](#tII-ol-0-0-11626){ref-type="table"}). The number of resected lymph nodes was similar between the two groups ([Table I](#tI-ol-0-0-11626){ref-type="table"}). The incidence of complications, surgery time, blood loss and postoperative mortality were not significantly different between the two groups ([Table II](#tII-ol-0-0-11626){ref-type="table"}).

[Fig. 1](#f1-ol-0-0-11626){ref-type="fig"} shows the rates of DFS and OS of all patients, whereas [Table III](#tIII-ol-0-0-11626){ref-type="table"} and [Fig. 2](#f2-ol-0-0-11626){ref-type="fig"} demonstrate the rates of DFS and OS in the LG and OG groups. The 75% DFS time was 15.6 (11.5--20.0) months for the OG group and 25.7 (12.3--41.3) months for the LG group. The 1-, 2-, 3- and 5-year OS rates for the LG group were 89.6, 82.1, 75.6 and 65.8%, respectively, and for the OG group were 81.6, 65.9, 55.9 and 49.7%, respectively. The 1-, 2-, 3- and 5-year DFS rates for LG group were 89.6, 79.8, 70.4 and 53.3%, respectively, and for OG group were 81.1, 64.4, 54.1 and 43.7%, respectively. No significant difference was observed in OS and DFS between the two groups. In addition, no significant difference was observed in 1-, 2-, 3- and 5-year DFS and OS.

Discussion
==========

According to the Clinical Practice Guidelines in Oncology Gastric Cancer (version 2.2018), patients with potentially resectable cT2 or higher, any N, and cM0 tumors are recommended to receive perioperative chemotherapy (category 1) or perioperative chemoradiaton (category 2B) ([@b14-ol-0-0-11626]). Previous randomized control trials and retrospective studies have demonstrated the safety and efficacy of LG for LAGC ([@b15-ol-0-0-11626]--[@b18-ol-0-0-11626]). However, the evidence of safety and long-term results of laparoscopic surgery for the treatment of LAGC after neoadjuvant therapy were scarce.

A higher number of patients underwent conventional OG following neoadjuvant therapy in the China National Cancer Center compared with those that underwent LG, which may be due to the following reasons. First, OG was selected for patients who were diagnosed with bulky lymph nodes or lymph nodes fused together by CT or MRI following neoadjuvant therapy. Second, a number of surgeons in the China National Cancer Center only perform OG. Third, several patients with severe coronary artery disease or pulmonary disease were assigned to the OG group for surgical safety.

The present study revealed that patients with LAGC that underwent LG after neoadjuvant therapy had significantly shorter postoperative stay compared to OG (11.1 vs. 13.0; P=0.020). A randomized controlled trial has confirmed that the benefits of the laparoscopic approach measured by early postoperative recovery can safely be offered to select patients with LAGC ([@b19-ol-0-0-11626]). The results from a prospective study also showed that laparoscopic distal gastrectomy after neoadjuvant therapy has comparable results with open distal gastrectomy in safety and efficacy in the short term ([@b20-ol-0-0-11626]).

The number of metastatic lymph nodes harvested in the LG group was less than that in the OG group (2.4 vs. 6.0; P\<0.0001). Laparoscopic procedures have certain limitations, such as difficult management of tumors with bulky metastasis-positive nodes or large primary tumors, and unusual tissue fibrosis or edema may present following neoadjuvant therapy, which further increases surgical difficulty ([@b21-ol-0-0-11626]). Therefore, the majority of doctors select conventional OG.

Resected lymph nodes, incidence of complications, surgery time, blood loss and postoperative mortality were not significantly different between the two groups. The results were consistent with previous reports, which confirm the benefit of the laparoscopic approach, measured by early postoperative recovery, and that it can be safely offered to select patients with LAGC after neoadjuvant therapy ([@b14-ol-0-0-11626],[@b15-ol-0-0-11626]).

The OS and DFS of the laparoscopic group were indicated to be longer than the open gastrectomy group; however, there were no statistically significant differences between the two groups. The 75% DFS time was 15.6 (11.5--20.0) months for the open surgery group and 25.7 (12.3--41.3) months for the laparoscopic surgery group (P=0.12). The upper confidence limit for the 75% OS time among the laparoscopic group could not be calculated due to the right-censoring of the data. The right-censoring may cause an underestimate of the mean survival time and its standard error. The major reason may be the small sample size; in addition, the follow-up time was short. The cycle of neoadjuvant therapy was statistically different between the two groups; however, it did not affect the long-term survival result of the study (data not shown).

Strengths and limitations should be considered when interpreting the study results. To the best of our knowledge, this cohort is the largest to date to compare the short-term and long-term survival outcomes between OG and LG for LAGC after neoadjuvant therapy. There were several limitations in this study. First, it is a retrospective study with a limited sample size in a single center. Second, patients were divided into different surgical approach groups, based on their personal choice, because either surgical type can be used according to doctors\' clinical judgments. Furthermore, the follow-up time was short, and follow-up of these patients is ongoing.

The results of this study demonstrated that LG for LAGC following neoadjuvant therapy may provide non-inferior short-term and long-term survival outcomes compared with open surgery, suggesting a laparoscopic approach may be justified for patients with LAGC after neoadjuvant therapy. Multicenter randomized controlled trials are required to investigate the positive effects of LG for LAGC following neoadjuvant therapy.
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###### 

Demographic and clinicopathological characteristics in laparoscopy and open gastrectomy group.

  Variable                                                        Laparoscopy group (n=49)^[a](#tfn1-ol-0-0-11626){ref-type="table-fn"}^   Open gastrectomy group (n=221)^[a](#tfn1-ol-0-0-11626){ref-type="table-fn"}^   P-value
  --------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------ --------------------------------------------------------
  Age, years                                                      54.4 (10.9)                                                              54.9 (11.3)                                                                    0.80
  Body mass index, kg/m^2^                                                                                                                                                                                                0.89
    \<18.5                                                        3 (6.1)                                                                  11 (5.0)                                                                       
    18.5--22.9                                                    22 (44.9)                                                                91 (41.2)                                                                      
    23.0--27.4                                                    20 (40.8)                                                                94 (42.5)                                                                      
    ≥27.5                                                         4 (8.2)                                                                  25 (11.3)                                                                      
  Sex, n (%)                                                                                                                                                                                                              0.97
    Male                                                          34 (69.4)                                                                154 (69.7)                                                                     
    Female                                                        15 (30.6)                                                                67 (30.3)                                                                      
  Comorbidities, n (%)                                                                                                                                                                                                    0.58
    Diabetes                                                      3 (6.1)                                                                  16 (7.2)                                                                       
    Coronary artery disease                                       0 (0.0)                                                                  11 (5.0)                                                                       
    Hypertension                                                  10 (20.4)                                                                42 (19.0)                                                                      
    Cerebral infraction                                           0 (0.0)                                                                  5 (2.3)                                                                        
    Hypothyroidism                                                0 (0.0)                                                                  2 (0.9)                                                                        
    Chronic obstructive pulmonary disease                         0 (0.0)                                                                  3 (1.4)                                                                        
    Hepatitis B                                                   0 (0.0)                                                                  4 (1.8)                                                                        
    Hepatitis C                                                   0 (0.0)                                                                  1 (0.5)                                                                        
  Previous abdominal surgery, n (%)                                                                                                                                                                                       0.78
    Yes                                                           5 (10.2)                                                                 19 (8.6)                                                                       
    No                                                            44 (89.8)                                                                202 (91.4)                                                                     
  Tumor location, n (%)                                                                                                                                                                                                   0.74
    Upper 1/3                                                     13 (26.5)                                                                54 (24.4)                                                                      
    Middle 1/3                                                    11 (22.5)                                                                44 (19.9)                                                                      
    Low 1/3                                                       9 (18.4)                                                                 61 (27.6)                                                                      
    Upper-middle                                                  3 (6.1)                                                                  16 (7.2)                                                                       
    Middle-low                                                    13 (26.5)                                                                45 (20.4)                                                                      
    Body-antrum                                                   0 (0.0)                                                                  1 (0.5)                                                                        
  Family history of cancer, n (%)                                                                                                                                                                                         0.47
    Yes                                                           13 (26.5)                                                                48 (21.7)                                                                      
    No                                                            36 (73.5)                                                                173 (78.3)                                                                     
  Clinical TNM stage, n (%)                                                                                                                                                                                               0.08
    II                                                            4 (8.2)                                                                  5 (2.3)                                                                        
    III                                                           45 (91.8)                                                                216 (95.5)                                                                     
  Neoadjuvant therapy regime, n (%)                                                                                                                                                                                       0.10
    XELOX                                                         3 (6.1)                                                                  11 (5.0)                                                                       
    FOLFOX                                                        1 (2.0)                                                                  19 (8.6)                                                                       
    SOX                                                           13 (26.5)                                                                53 (24.0)                                                                      
    SP                                                            2 (4.1)                                                                  19 (8.6)                                                                       
    TXT+XELOX                                                     6 (12.2)                                                                 17 (7.7)                                                                       
    TCF                                                           5 (10.2)                                                                 28 (12.7)                                                                      
    DOS                                                           7 (14.3)                                                                 20 (9.1)                                                                       
    TXT+SP                                                        0 (0.0)                                                                  14 (6.3)                                                                       
    Others                                                        5 (10.2)                                                                 28 (12.7)                                                                      
  Cycle of neoadjuvant therapy, n (%)                                                                                                                                                                                     0.02^[b](#tfn2-ol-0-0-11626){ref-type="table-fn"}^
    1-3                                                           23 (46.9)                                                                87 (39.4)                                                                      
    4-6                                                           21 (42.9)                                                                117 (52.9)                                                                     
    \>6                                                           0 (0.0)                                                                  12 (5.4)                                                                       
  Neoadjuvant therapy toxicity, n (%)                                                                                                                                                                                     0.47
    No toxicity                                                   13 (26.5)                                                                74 (33.5)                                                                      
    Grade I/II                                                    33 (67.4)                                                                128 (57.9)                                                                     
    Grade III/IV                                                  3 (6.1)                                                                  19 (8.6)                                                                       
  Time between neoadjuvant therapy and surgery, days              36.4 (15.4)                                                              36.9 (18.0)                                                                    0.86
  RECIST criteria (version 1.1), n (%)                                                                                                                                                                                    0.93
    Partial response                                              34 (69.4)                                                                150 (67.9)                                                                     
    Stable disease                                                13 (26.5)                                                                64 (29.0)                                                                      
    Progressive disease                                           2 (4.1)                                                                  7 (3.1)                                                                        
  Gastrectomy, n (%)                                                                                                                                                                                                      0.63
    Distal                                                        29 (59.2)                                                                117 (52.9)                                                                     
    Proximal                                                      4 (8.2)                                                                  27 (12.2)                                                                      
    Total                                                         16 (32.7)                                                                77 (34.8)                                                                      
  Borrmann type ([@b22-ol-0-0-11626]), n (%)                                                                                                                                                                              0.37
    I                                                             4 (8.2)                                                                  8 (3.6)                                                                        
    II                                                            18 (36.7)                                                                62 (28.1)                                                                      
    III                                                           23 (46.9)                                                                123 (55.7)                                                                     
    IV                                                            4 (8.2)                                                                  25 (11.3)                                                                      
    Unknown                                                       0 (0.0)                                                                  3 (1.4)                                                                        
  Lauren type ([@b23-ol-0-0-11626]), n (%)                                                                                                                                                                                0.35
    Intestinal                                                    13 (26.5)                                                                43 (19.5)                                                                      
    Diffuse                                                       17 (34.7)                                                                66 (29.9)                                                                      
    Mixed                                                         8 (16.3)                                                                 34 (15.4)                                                                      
    Unknown                                                       11 (22.5)                                                                78 (35.3)                                                                      
  Primary pathology, n (%)                                                                                                                                                                                                0.65
    Poorly differentiated adenocarcinoma                          32 (65.3)                                                                146 (66.1)                                                                     
    Moderately differentiated adenocarcinoma                      10 (20.4)                                                                31 (14.0)                                                                      
    Well differentiated adenocarcinoma                            1 (2.0)                                                                  3 (1.4)                                                                        
    Signet ring cell carcinoma                                    1 (2.0)                                                                  13 (5.9)                                                                       
    Minor adenocarcinoma remains                                  2 (4.1)                                                                  6 (2.7)                                                                        
    No adenocarcinoma remains (complete response)                 2 (4.1)                                                                  18 (8.1)                                                                       
    Other                                                         1 (2.0)                                                                  4 (1.8)                                                                        
  Resected lymph nodes, n (%)                                     32.9 (13.6)                                                              30.0 (14.0)                                                                    0.19
  Metastatic lymph nodes, n (%)                                   2.4 (3.4)                                                                6.0 (9.1)                                                                      \<0.0001^[b](#tfn2-ol-0-0-11626){ref-type="table-fn"}^
  Mandard Tumor Regression Grading ([@b12-ol-0-0-11626]), n (%)                                                                                                                                                           0.06
    1                                                             2 (4.1)                                                                  17 (7.7)                                                                       
    2                                                             10 (20.4)                                                                32 (14.5)                                                                      
    3                                                             22 (44.9)                                                                62 (28.1)                                                                      
    4                                                             2 (4.1)                                                                  8 (3.6)                                                                        
    5                                                             13 (26.5)                                                                102 (46.2)                                                                     

Data are presented as the mean (standard deviation) for continuous variables and number (percentage) for categorical variables.

P\<0.05. XELOX, oxaliplatin and capecitabine; FOLFOX, folinic acid, fluorouracil and oxaliplatin; SOX, S-1 and oxaliplatin; SP, S-1/cisplatin; TXT, docetaxel; TCF, docetaxel, carboplatin and 5-fluorouracil; DOS, docetaxel, oxaliplatin and S-1; RECIST, response evaluation criteria in solid tumors.

###### 

Comparison of perioperative parameters between the laparoscopic and open gastrectomy groups.

  Variable                          Laparoscopy group (n=49)^[a](#tfn3-ol-0-0-11626){ref-type="table-fn"}^   Open gastrectomy group (n=221)^[a](#tfn3-ol-0-0-11626){ref-type="table-fn"}^   P-value
  --------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------------ -----------------------------------------------------
  Complication, n (%)               6 (12.2)                                                                 26 (11.8)                                                                      0.752
    Central line infection          0 (0.0)                                                                  1 (0.5)                                                                        
    Wound infection                 0 (0.0)                                                                  3 (1.4)                                                                        
    Renal failure                   0 (0.0)                                                                  1 (0.5)                                                                        
    Multiple organ failure          0 (0.0)                                                                  1 (0.5)                                                                        
    Delayed gastric emptying        1 (2.0)                                                                  1 (0.5)                                                                        
    Gastrointestinal hemorrhage     0 (0.0)                                                                  5 (2.3)                                                                        
    Pleural effusion                1 (2.0)                                                                  2 (0.9)                                                                        
    Pneumonia                       0 (0.0)                                                                  3 (1.4)                                                                        
    Fat liquefaction                1 (2.0)                                                                  2 (0.9)                                                                        
    Postoperative ileus             0 (0.0)                                                                  3 (1.4)                                                                        
    Intra-abdominal infection       1 (2.0)                                                                  3 (1.4)                                                                        
    Duodenal stump fistula          1 (2.0)                                                                  1 (0.5)                                                                        
    Anastomotic leak                1 (2.0)                                                                  4 (1.8)                                                                        
    Reoperation                     1 (2.0)                                                                  1 (0.5)                                                                        
    Postoperative mortality         0 (0.0)                                                                  0 (0.0)                                                                        
  Surgery time, min                 221.5 (69.9)                                                             201.1 (56.7)                                                                   0.060
  Estimated blood loss, ml          260.2 (232.1)                                                            241.1 (186.3)                                                                  0.590
  Time to pull gastric tube, days   5.5 (2.0)                                                                6.6 (3.3)                                                                      0.002^[b](#tfn4-ol-0-0-11626){ref-type="table-fn"}^
  Postoperative stay, days          11.1 (4.4)                                                               13.0 (7.3)                                                                     0.020^[b](#tfn4-ol-0-0-11626){ref-type="table-fn"}^

Data are presented as the mean (standard deviation) for continuous variables and number (percentage) for categorical variables.

###### 

Comparison of survival status between laparoscopic and gastrectomy group.

  Variable                                                    Laparoscopy group (n=49)                                     Open gastrectomy group (n=221)   P-value
  ----------------------------------------------------------- ------------------------------------------------------------ -------------------------------- ---------
  DFS, months^[a](#tfn4-ol-0-0-11626){ref-type="table-fn"}^   25.7 (12.3--41.3)                                            15.6 (11.5--20.0)                0.27
    1-year rate                                               0.896                                                        0.811                            
    2-year rate                                               0.798                                                        0.644                            
    3-year rate                                               0.704                                                        0.541                            
    5-year rate                                               0.533                                                        0.437                            
  OS, months^[a](#tfn4-ol-0-0-11626){ref-type="table-fn"}^    39.5 (12.3-)^[b](#tfn5-ol-0-0-11626){ref-type="table-fn"}^   16.1 (12.1--22.1)                0.12
    1-year rate                                               0.896                                                        0.816                            
    2-year rate                                               0.821                                                        0.659                            
    3-year rate                                               0.756                                                        0.559                            
    5-year rate                                               0.658                                                        0.497                            

75% survival time; since survival rate at the longest time point exceeds 50% for the laparoscopic group, median survival time could not be computed.

The upper confidence limit for the 75% OS time among the laparoscopic group could not be calculated due to the right-censoring of the data. OS and DFS times are presented as the mean (95% confidence interval). DFS, disease-free survival; OS, overall survival.
